MA27730A1 - Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete - Google Patents

Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete

Info

Publication number
MA27730A1
MA27730A1 MA28561A MA28561A MA27730A1 MA 27730 A1 MA27730 A1 MA 27730A1 MA 28561 A MA28561 A MA 28561A MA 28561 A MA28561 A MA 28561A MA 27730 A1 MA27730 A1 MA 27730A1
Authority
MA
Morocco
Prior art keywords
phenyl
combinations
methylamide
paroxetine
piperazin
Prior art date
Application number
MA28561A
Other languages
English (en)
Inventor
Melotto Sergio
Corsi Mauro
Carletti Renzo
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27730A1 publication Critical patent/MA27730A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Associations de paroxétine et de [1-(R)-(3,5-bis-trifluorométhylphényl)-éthyl]méthylamide d'acide 4-(S)-(4-acétyl-pipérazine-1-yl)-2-(R)-(4-fluoro-2-méthyl-pipéridine-1-carboxylique pour le traitement de la dépression et de l'anxiété La présente invention concerne des associations thérapeutiques comprenant de la paroxétine ou ses sels ou produits de solvatation physiologiquement acceptables et du [1-(R)-(3,5-bis-trifluorométhylphényl)-éthyl]-méthylamide d'acide 4-(S)-{4-acétyl-pipérazine-1-yl)-2-(R)-(4-fluoro-2-méthyl-phényl)-pipéridine-1-carboxylique ou de ses sels ou produits de solvatation pharmaceutiquement acceptables, des compositions pharmaceutiques contenant lesdites associations et leur utilisation dans le traitement de la dépression et/ou de l'anxiété.
MA28561A 2003-04-17 2005-10-19 Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete MA27730A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments

Publications (1)

Publication Number Publication Date
MA27730A1 true MA27730A1 (fr) 2006-01-02

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
MA28561A MA27730A1 (fr) 2003-04-17 2005-10-19 Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
MA28562A MA27731A1 (fr) 2003-04-17 2005-10-19 Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA28562A MA27731A1 (fr) 2003-04-17 2005-10-19 Combinaison comprenant paroxetine et 2-(s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-acide carboxylique [1- (r)-(3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide destinee au traitement de la depression et/ou de l'anxiete

Country Status (18)

Country Link
US (4) US20060241124A1 (fr)
EP (4) EP1613325A1 (fr)
JP (4) JP2006523651A (fr)
KR (2) KR20060003876A (fr)
CN (2) CN1809355A (fr)
AU (2) AU2004229181A1 (fr)
BR (2) BRPI0409379A (fr)
CA (2) CA2522313A1 (fr)
CO (1) CO5700753A2 (fr)
GB (1) GB0308968D0 (fr)
IS (2) IS8128A (fr)
MA (2) MA27730A1 (fr)
MX (2) MXPA05011063A (fr)
NO (2) NO20055367L (fr)
PL (2) PL377858A1 (fr)
RU (2) RU2005135647A (fr)
WO (4) WO2004091616A1 (fr)
ZA (2) ZA200508067B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (fr) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Forme dosifee stable d'un antidepresseur
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
WO2012175434A1 (fr) * 2011-06-20 2012-12-27 Glaxo Group Limited Formulations pharmaceutiques comprenant du vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU735760B2 (en) * 1997-04-24 2001-07-12 Merck Sharp & Dohme Limited Use of a NK-1 receptor antagonist and an SSRI for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
HK1045308A1 (zh) * 1999-12-17 2002-11-22 Schering Corporation 选择性神经激肽拮抗物
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
PY0117895A (es) * 2000-07-31 2003-11-03 Pfizer Prod Inc Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
JP4459621B2 (ja) * 2001-11-13 2010-04-28 シェーリング コーポレイション Ｎｋ１アンタゴニスト
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JP2006523651A (ja) 2006-10-19
KR20060003875A (ko) 2006-01-11
US20060217395A1 (en) 2006-09-28
BRPI0409379A (pt) 2006-04-25
PL377857A1 (pl) 2006-02-20
JP2006523650A (ja) 2006-10-19
MXPA05011064A (es) 2006-04-18
PL377858A1 (pl) 2006-02-20
CA2522311A1 (fr) 2004-10-28
CN1809359A (zh) 2006-07-26
WO2004091624A1 (fr) 2004-10-28
AU2004229181A1 (en) 2004-10-28
RU2005135647A (ru) 2006-06-10
JP2006523652A (ja) 2006-10-19
BRPI0409377A (pt) 2006-04-25
CO5700753A2 (es) 2006-11-30
IS8128A (is) 2005-11-15
JP2006523649A (ja) 2006-10-19
IS8129A (is) 2005-11-15
WO2004091617A1 (fr) 2004-10-28
ZA200508067B (en) 2007-02-28
NO20055367L (no) 2005-11-14
KR20060003876A (ko) 2006-01-11
CN1809355A (zh) 2006-07-26
US20060241124A1 (en) 2006-10-26
EP1615641A1 (fr) 2006-01-18
ZA200508068B (en) 2007-02-28
EP1613325A1 (fr) 2006-01-11
AU2004229179A1 (en) 2004-10-28
WO2004091616A1 (fr) 2004-10-28
US20060241143A1 (en) 2006-10-26
GB0308968D0 (en) 2003-05-28
US20060287325A1 (en) 2006-12-21
EP1615642A1 (fr) 2006-01-18
MA27731A1 (fr) 2006-01-02
EP1653956A1 (fr) 2006-05-10
CA2522313A1 (fr) 2004-10-28
NO20055368L (no) 2005-11-14
WO2004091615A1 (fr) 2004-10-28
RU2005135649A (ru) 2006-03-20
MXPA05011063A (es) 2005-12-12

Similar Documents

Publication Publication Date Title
Hahn et al. An in vitro assessment of the strength of porcelain veneers dependent on tooth preparation
EP1651195A4 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
JP2005532372A5 (fr)
EP1562897A4 (fr) Inhibiteurs de beta-secretase phenylcarboxamide utilises dans le traitement de la maladie d'alzheimer
TNSN04104A1 (fr) Formulations pharmaceutiques de derives de platine.
ATE269846T1 (de) N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
MA27730A1 (fr) Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
BRPI0414448A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
BR0312410A (pt) Formulações farmacêuticas de liberação controlada
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
SE9902937D0 (sv) Pharmaceutical compositions
BR0005318A (pt) Utilização de inibidores de secreção da apo b/mtp e agentes antiobesidade
MA27474A1 (fr) Vaccin
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
WO2002053099A3 (fr) Methodes et compositions de traitement d'une parodontopathie
CA2368352A1 (fr) Procede de traitement de la neuro degenerescence
MA28224A1 (fr) Nitro-oxyderives de medicaments contre l'hypertension.
EP2452674A3 (fr) Compositions et procédés pour augmenter les niveaux de plaquettes dans le sang chez les êtres humains
SE9902936D0 (sv) Pharmaceutical compositions
KR970032865A (ko) 허혈성 심질환으로 고생하는 환자의 경색크기를 감소하기 위한 방법
ATE384521T1 (de) Medikament zur behandlung von durch parasitären protozoen verursachte erkrankungen